Progressive Keratoconus

3
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Glaukos
GlaukosALISO VIEJO, CA
3 programs
1
2
Test Article APhase 31 trial
riboflavin ophthalmic solutionPhase 31 trial
NXL Energy 1Phase 1/21 trial
Active Trials
NCT05314738RecruitingEst. Feb 2026
NCT03442751CompletedEst. Aug 2020
NCT00647699CompletedEst. Apr 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GlaukosTest Article A
Glaukosriboflavin ophthalmic solution
GlaukosNXL Energy 1

Clinical Trials (3)

NCT03442751GlaukosTest Article A

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

Start: Apr 2018Est. completion: Aug 2020
Phase 3Completed
NCT00647699Glaukosriboflavin ophthalmic solution

Corneal Collagen Cross-linking for Progressive Keratoconus

Start: Dec 2007Est. completion: Apr 2011
Phase 3Completed
NCT05314738GlaukosNXL Energy 1

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

Start: Mar 2022Est. completion: Feb 2026
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space